<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p87" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_87{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t2_87{left:341px;bottom:30px;}
#t3_87{left:348px;bottom:25px;letter-spacing:0.11px;}
#t4_87{left:377px;bottom:30px;}
#t5_87{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t6_87{left:540px;bottom:30px;}
#t7_87{left:546px;bottom:25px;letter-spacing:0.07px;}
#t8_87{left:44px;bottom:77px;letter-spacing:0.1px;word-spacing:-0.05px;}
#t9_87{left:44px;bottom:63px;letter-spacing:0.1px;}
#ta_87{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#tb_87{left:285px;bottom:827px;letter-spacing:-0.29px;}
#tc_87{left:996px;bottom:873px;letter-spacing:-0.1px;}
#td_87{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#te_87{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#tf_87{left:1130px;bottom:28px;letter-spacing:0.17px;}
#tg_87{left:36px;bottom:182px;}
#th_87{left:46px;bottom:176px;letter-spacing:0.13px;}
#ti_87{left:261px;bottom:176px;}
#tj_87{left:36px;bottom:165px;}
#tk_87{left:42px;bottom:159px;letter-spacing:0.13px;word-spacing:-0.06px;}
#tl_87{left:310px;bottom:159px;}
#tm_87{left:36px;bottom:148px;}
#tn_87{left:42px;bottom:142px;letter-spacing:0.13px;word-spacing:-0.02px;}
#to_87{left:875px;bottom:142px;}
#tp_87{left:36px;bottom:131px;}
#tq_87{left:46px;bottom:125px;letter-spacing:0.13px;}
#tr_87{left:45px;bottom:108px;letter-spacing:0.13px;}
#ts_87{left:714px;bottom:108px;letter-spacing:0.14px;}
#tt_87{left:820px;bottom:108px;}
#tu_87{left:444px;bottom:778px;letter-spacing:0.44px;word-spacing:-0.28px;}
#tv_87{left:734px;bottom:778px;letter-spacing:0.44px;word-spacing:-0.28px;}
#tw_87{left:36px;bottom:488px;letter-spacing:-0.09px;}
#tx_87{left:36px;bottom:470px;letter-spacing:-0.11px;}
#ty_87{left:294px;bottom:695px;letter-spacing:-0.11px;}
#tz_87{left:444px;bottom:712px;letter-spacing:-0.1px;}
#t10_87{left:611px;bottom:719px;}
#t11_87{left:444px;bottom:693px;letter-spacing:-0.1px;}
#t12_87{left:444px;bottom:675px;letter-spacing:-0.08px;}
#t13_87{left:730px;bottom:747px;letter-spacing:-0.09px;}
#t14_87{left:730px;bottom:730px;letter-spacing:-0.1px;}
#t15_87{left:867px;bottom:738px;}
#t16_87{left:730px;bottom:714px;letter-spacing:-0.09px;}
#t17_87{left:730px;bottom:697px;}
#t18_87{left:730px;bottom:680px;letter-spacing:-0.09px;}
#t19_87{left:730px;bottom:663px;letter-spacing:-0.1px;}
#t1a_87{left:837px;bottom:671px;}
#t1b_87{left:294px;bottom:481px;letter-spacing:-0.11px;}
#t1c_87{left:444px;bottom:508px;letter-spacing:-0.09px;}
#t1d_87{left:444px;bottom:490px;letter-spacing:-0.09px;}
#t1e_87{left:571px;bottom:497px;}
#t1f_87{left:444px;bottom:471px;letter-spacing:-0.1px;}
#t1g_87{left:444px;bottom:453px;letter-spacing:-0.08px;}
#t1h_87{left:730px;bottom:535px;letter-spacing:-0.1px;}
#t1i_87{left:869px;bottom:542px;}
#t1j_87{left:730px;bottom:518px;letter-spacing:-0.09px;}
#t1k_87{left:730px;bottom:501px;letter-spacing:-0.11px;}
#t1l_87{left:730px;bottom:484px;}
#t1m_87{left:730px;bottom:468px;letter-spacing:-0.09px;}
#t1n_87{left:730px;bottom:451px;letter-spacing:-0.1px;}
#t1o_87{left:838px;bottom:458px;}
#t1p_87{left:294px;bottom:579px;letter-spacing:-0.11px;}
#t1q_87{left:294px;bottom:379px;letter-spacing:-0.11px;}
#t1r_87{left:294px;bottom:246px;letter-spacing:-0.11px;}
#t1s_87{left:444px;bottom:598px;letter-spacing:-0.1px;}
#t1t_87{left:524px;bottom:605px;}
#t1u_87{left:444px;bottom:579px;letter-spacing:-0.1px;}
#t1v_87{left:444px;bottom:561px;letter-spacing:-0.08px;}
#t1w_87{left:730px;bottom:629px;letter-spacing:-0.17px;}
#t1x_87{left:868px;bottom:636px;}
#t1y_87{left:731px;bottom:612px;letter-spacing:-0.1px;word-spacing:0.01px;}
#t1z_87{left:731px;bottom:595px;}
#t20_87{left:731px;bottom:579px;letter-spacing:-0.09px;}
#t21_87{left:731px;bottom:562px;letter-spacing:-0.1px;}
#t22_87{left:838px;bottom:569px;}
#t23_87{left:444px;bottom:419px;letter-spacing:-0.08px;}
#t24_87{left:444px;bottom:401px;letter-spacing:-0.06px;}
#t25_87{left:444px;bottom:382px;letter-spacing:-0.1px;}
#t26_87{left:535px;bottom:390px;}
#t27_87{left:444px;bottom:364px;letter-spacing:-0.06px;}
#t28_87{left:444px;bottom:346px;letter-spacing:-0.1px;}
#t29_87{left:583px;bottom:353px;}
#t2a_87{left:444px;bottom:301px;letter-spacing:-0.08px;}
#t2b_87{left:444px;bottom:283px;letter-spacing:-0.06px;}
#t2c_87{left:444px;bottom:265px;letter-spacing:-0.09px;}
#t2d_87{left:444px;bottom:246px;letter-spacing:-0.06px;}
#t2e_87{left:444px;bottom:228px;letter-spacing:-0.1px;}
#t2f_87{left:535px;bottom:235px;}
#t2g_87{left:444px;bottom:210px;letter-spacing:-0.06px;}
#t2h_87{left:444px;bottom:191px;letter-spacing:-0.1px;}
#t2i_87{left:583px;bottom:199px;}
#t2j_87{left:918px;bottom:612px;letter-spacing:-0.1px;}
#t2k_87{left:918px;bottom:594px;letter-spacing:-0.09px;}
#t2l_87{left:918px;bottom:575px;letter-spacing:-0.08px;}
#t2m_87{left:1061px;bottom:545px;letter-spacing:-0.09px;}
#t2n_87{left:1061px;bottom:526px;letter-spacing:-0.08px;}
#t2o_87{left:1061px;bottom:508px;letter-spacing:-0.09px;}
#t2p_87{left:1061px;bottom:490px;letter-spacing:-0.1px;}
#t2q_87{left:1061px;bottom:471px;letter-spacing:-0.09px;}
#t2r_87{left:1061px;bottom:453px;letter-spacing:-0.1px;}
#t2s_87{left:1061px;bottom:435px;letter-spacing:-0.11px;}
#t2t_87{left:734px;bottom:369px;letter-spacing:-0.1px;}
#t2u_87{left:734px;bottom:349px;letter-spacing:-0.09px;}
#t2v_87{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_87{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s1_87{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s2_87{font-size:12px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_87{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_87{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s5_87{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s6_87{font-size:12px;font-family:ArialMT_5tg;color:#000;}
.s7_87{font-size:15px;font-family:ArialMT_5tg;color:#0065A4;}
.s8_87{font-size:15px;font-family:ArialMT_5tg;color:#000;}
.s9_87{font-size:15px;font-family:ArialMT_k0;color:#000;}
.sa_87{font-size:14px;font-family:Arial-BoldMT_5te;color:#000;}
.sb_87{font-size:17px;font-family:Arial-BoldMT_5te;color:#0065A4;}
.sc_87{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts87" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: ArialMT_k0;
	src: url("fonts/ArialMT_k0.woff") format("woff");
}

</style>
<div id="pg87Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg87" style="-webkit-user-select: none;"><object width="1210" height="935" data="87/87.svg" type="image/svg+xml" id="pdf87" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_87" class="t s0_87">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_87" class="t s1_87">® </span>
<span id="t3_87" class="t s0_87">(NCCN </span>
<span id="t4_87" class="t s1_87">® </span>
<span id="t5_87" class="t s0_87">), All rights reserved. NCCN Guidelines </span>
<span id="t6_87" class="t s1_87">® </span>
<span id="t7_87" class="t s0_87">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_87" class="t s2_87">Note: All recommendations are category 2A unless otherwise indicated. </span>
<span id="t9_87" class="t s2_87">Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. </span>
<span id="ta_87" class="t s3_87">NCCN Guidelines Version 4.2024 </span>
<span id="tb_87" class="t s3_87">Mucosal Melanoma </span>
<span id="tc_87" class="t s4_87">NCCN Guidelines Index </span>
<span id="td_87" class="t s4_87">Table of Contents </span>
<span id="te_87" class="t s4_87">Discussion </span>
<span id="tf_87" class="t s5_87">MM-2 </span>
<span id="tg_87" class="t s6_87">h </span>
<span id="th_87" class="t s7_87">Principles of Surgery (SURG-A)</span><span id="ti_87" class="t s8_87">. </span>
<span id="tj_87" class="t s6_87">i </span>
<span id="tk_87" class="t s7_87">Principles of Radiation Therapy (MM-A)</span><span id="tl_87" class="t s8_87">. </span>
<span id="tm_87" class="t s6_87">j </span>
<span id="tn_87" class="t s7_87">See Systemic Therapy for Metastatic or Unresectable Disease (ME-I) from the NCCN Guidelines for Melanoma: Cutaneous</span><span id="to_87" class="t s8_87">. </span>
<span id="tp_87" class="t s6_87">k </span>
<span id="tq_87" class="t s8_87">While adjuvant systemic therapy may be used for mucosal melanoma, data to support its use are far fewer than for cutaneous </span>
<span id="tr_87" class="t s9_87">melanoma. Options may include nivolumab (category 2B) or cisplatin/temozolomide (category 2B). </span><span id="ts_87" class="t s7_87">See Discussion</span><span id="tt_87" class="t s8_87">. </span>
<span id="tu_87" class="t s5_87">PRIMARY TREATMENT </span><span id="tv_87" class="t s5_87">ADJUVANT TREATMENT </span>
<span id="tw_87" class="t s5_87">Sinus or nasal cavity </span>
<span id="tx_87" class="t s5_87">mucosal melanoma </span>
<span id="ty_87" class="t s5_87">T3,N0 </span>
<span id="tz_87" class="t s5_87">Resection of primary </span>
<span id="t10_87" class="t sa_87">h </span>
<span id="t11_87" class="t s5_87">or </span>
<span id="t12_87" class="t s5_87">Clinical trial </span>
<span id="t13_87" class="t s5_87">Strongly consider </span>
<span id="t14_87" class="t s5_87">postoperative RT </span>
<span id="t15_87" class="t sa_87">i </span>
<span id="t16_87" class="t s5_87">to primary site </span>
<span id="t17_87" class="t s5_87">± </span>
<span id="t18_87" class="t s5_87">Systemic therapy </span>
<span id="t19_87" class="t s5_87">(category 2B) </span>
<span id="t1a_87" class="t sa_87">k </span>
<span id="t1b_87" class="t s5_87">T3–T4a,N1 </span>
<span id="t1c_87" class="t s5_87">Resection + neck dissection </span>
<span id="t1d_87" class="t s5_87">of positive neck </span>
<span id="t1e_87" class="t sa_87">h </span>
<span id="t1f_87" class="t s5_87">or </span>
<span id="t1g_87" class="t s5_87">Clinical trial </span>
<span id="t1h_87" class="t s5_87">Postoperative RT </span>
<span id="t1i_87" class="t sa_87">i </span>
<span id="t1j_87" class="t s5_87">to primary site and </span>
<span id="t1k_87" class="t s5_87">neck </span>
<span id="t1l_87" class="t s5_87">± </span>
<span id="t1m_87" class="t s5_87">Systemic therapy </span>
<span id="t1n_87" class="t s5_87">(category 2B) </span>
<span id="t1o_87" class="t sa_87">k </span>
<span id="t1p_87" class="t s5_87">T4a,N0 </span>
<span id="t1q_87" class="t s5_87">T4b,N0 </span>
<span id="t1r_87" class="t s5_87">T4b,N1 </span>
<span id="t1s_87" class="t s5_87">Resection </span>
<span id="t1t_87" class="t sa_87">h </span>
<span id="t1u_87" class="t s5_87">or </span>
<span id="t1v_87" class="t s5_87">Clinical trial </span>
<span id="t1w_87" class="t s5_87">Postoperative RT </span>
<span id="t1x_87" class="t sa_87">i </span>
<span id="t1y_87" class="t s5_87">to primary site </span>
<span id="t1z_87" class="t s5_87">± </span>
<span id="t20_87" class="t s5_87">Systemic therapy </span>
<span id="t21_87" class="t s5_87">(category 2B) </span>
<span id="t22_87" class="t sa_87">k </span>
<span id="t23_87" class="t s5_87">Clinical trial (preferred) </span>
<span id="t24_87" class="t s5_87">or </span>
<span id="t25_87" class="t s5_87">Primary RT </span>
<span id="t26_87" class="t sa_87">i </span>
<span id="t27_87" class="t s5_87">or </span>
<span id="t28_87" class="t s5_87">Systemic therapy </span>
<span id="t29_87" class="t sa_87">j </span>
<span id="t2a_87" class="t s5_87">Clinical trial (preferred) </span>
<span id="t2b_87" class="t s5_87">or </span>
<span id="t2c_87" class="t s5_87">Best supportive care </span>
<span id="t2d_87" class="t s5_87">or </span>
<span id="t2e_87" class="t s5_87">Primary RT </span>
<span id="t2f_87" class="t sa_87">i </span>
<span id="t2g_87" class="t s5_87">or </span>
<span id="t2h_87" class="t s5_87">Systemic therapy </span>
<span id="t2i_87" class="t sa_87">j </span>
<span id="t2j_87" class="t s5_87">Follow-up </span>
<span id="t2k_87" class="t sb_87">(FOLL-A, 1 </span>
<span id="t2l_87" class="t sb_87">of 2) </span>
<span id="t2m_87" class="t s5_87">Recurrent or </span>
<span id="t2n_87" class="t s5_87">persistent </span>
<span id="t2o_87" class="t s5_87">disease </span>
<span id="t2p_87" class="t sb_87">(NCCN </span>
<span id="t2q_87" class="t sb_87">Guidelines for </span>
<span id="t2r_87" class="t sb_87">Melanoma: </span>
<span id="t2s_87" class="t sb_87">Cutaneous) </span>
<span id="t2t_87" class="t sb_87">Post Systemic Therapy/RT or RT </span>
<span id="t2u_87" class="t sb_87">Neck Evaluation (FOLL-A, 2 of 2) </span>
<span id="t2v_87" class="t sc_87">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
